IN
Live price temporarily unavailable.
Price history
Inspire Medical Systems (INSP) is a Health Care company in the Russell 2000. Latest news and coverage below.
IPO: May 3, 2018 · $16.00 offering · NYSE · View IPO details →
Inspire Medical Systems revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $16.4M | $28.6M | $50.6M | $82.0M | $115.4M | $233.4M | $407.9M | $624.8M | $802.8M | $912.0M |
| Growth (year over year) | — | +73.9% | +77.1% | +62.2% | +40.6% | +102.3% | +74.7% | +53.2% | +28.5% | +13.6% |
| Gross profit | $12.5M | $22.5M | $40.5M | $68.4M | $97.8M | $200.1M | $341.7M | $528.2M | $679.8M | $778.8M |
| Gross margin | 76.2% | 78.9% | 80.1% | 83.4% | 84.7% | 85.7% | 83.8% | 84.5% | 84.7% | 85.4% |
| Operating income | −$17.3M | −$16.0M | −$20.4M | −$34.9M | −$56.2M | −$39.9M | −$47.6M | −$40.3M | $36.1M | $51.0M |
| Operating margin | −105.0% | −56.0% | −40.3% | −42.5% | −48.7% | −17.1% | −11.7% | −6.4% | 4.5% | 5.6% |
| Net income | −$18.5M | −$17.5M | −$21.8M | −$33.2M | −$57.2M | −$42.0M | −$44.9M | −$21.2M | $53.5M | $145.4M |
| Net margin | −112.8% | −61.3% | −43.1% | −40.5% | −49.6% | −18.0% | −11.0% | −3.4% | 6.7% | 15.9% |
| EPS (diluted) | −$16.90 | −$14.88 | −$1.50 | −$1.40 | −$2.19 | −$1.54 | −$1.60 | −$0.72 | $1.75 | $4.89 |
| Balance sheet | ||||||||||
| Cash and equivalents | $6.68M | $8.96M | $97.3M | $22.9M | $190.5M | $214.5M | $441.6M | $185.5M | $150.2M | $104.8M |
| Total assets | — | $25.1M | $200.1M | $181.3M | $281.2M | $295.1M | $564.9M | $676.8M | $808.4M | $907.3M |
| Total liabilities | — | $23.8M | $36.1M | $41.4M | $51.4M | $66.0M | $68.9M | $104.3M | $118.7M | $126.2M |
| Long-term debt | — | — | $24.5M | $24.5M | $24.5M | $24.5M | — | — | — | — |
| Shareholders' equity | −$6.61M | $1.33M | $164.0M | $139.8M | $229.7M | $229.0M | $496.0M | $572.5M | $689.7M | $781.2M |
| Cash flow | ||||||||||
| Operating cash flow | −$17.9M | −$15.8M | −$18.7M | −$32.8M | −$53.0M | −$20.1M | $11.6M | $24.7M | $130.2M | $117.0M |
| Capital expenditure | $306.0K | $412.0K | $250.0K | $2.74M | $2.46M | $4.67M | $9.10M | $23.6M | $39.1M | $38.5M |
| Free cash flow | −$18.3M | −$16.2M | −$18.9M | −$35.6M | −$55.5M | −$24.8M | $2.47M | $1.02M | $91.1M | $78.5M |
| Share buybacks | — | — | — | — | — | — | $0 | $0 | $0 | $175.0M |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $203.2M | $239.7M | $201.3M | $217.1M | $224.5M | $269.1M | $204.6M | $200.6M |
| Growth (year over year) | +32.5% | +24.5% | +22.7% | +10.8% | +10.5% | +12.2% | +1.6% | −7.6% |
| Gross profit | $170.8M | $203.7M | $170.6M | $182.4M | $192.7M | $233.0M | $176.9M | $171.5M |
| Gross margin | 84.1% | 85.0% | 84.7% | 84.0% | 85.8% | 86.6% | 86.5% | 85.5% |
| Operating income | $14.3M | $31.9M | −$1.49M | −$3.32M | $9.64M | $46.1M | −$1.12M | −$514.0K |
| Operating margin | 7.0% | 13.3% | −0.7% | −1.5% | 4.3% | 17.1% | −0.5% | −0.3% |
| Net income | $18.5M | $35.2M | $2.99M | −$3.59M | $9.93M | $136.1M | −$11.3M | $314.0K |
| Net margin | 9.1% | 14.7% | 1.5% | −1.7% | 4.4% | 50.6% | −5.5% | 0.2% |
| EPS (diluted) | $0.60 | $1.17 | $0.10 | −$0.12 | $0.34 | $4.57 | −$0.39 | $0.01 |
| Balance sheet | ||||||||
| Cash and equivalents | $147.5M | $150.2M | $53.9M | $106.9M | $112.8M | $104.8M | $98.9M | $127.8M |
| Total assets | $796.2M | $808.4M | $730.8M | $802.2M | $807.7M | $907.3M | $911.4M | $926.0M |
| Total liabilities | $99.6M | $118.7M | $95.1M | $124.4M | $141.3M | $126.2M | $119.0M | $100.4M |
| Shareholders' equity | $696.6M | $689.7M | $635.7M | $677.8M | $666.5M | $781.2M | $792.3M | $825.6M |
| Cash flow | ||||||||
| Operating cash flow | $52.3M | $69.2M | −$6.70M | $2.68M | $68.5M | $52.5M | $12.8M | $23.2M |
| Capital expenditure | $8.01M | $7.03M | $8.41M | $9.00M | $10.4M | $10.7M | $9.73M | $9.16M |
| Free cash flow | $44.3M | $62.2M | −$15.1M | −$6.31M | $58.1M | $41.8M | $3.12M | $14.1M |
| Share buybacks | $0 | $0 | $75.0M | $0 | $50.0M | $50.0M | $0 | $0 |
From Inspire Medical Systems's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Inspire Medical Systems
- Headquarters
- Golden Valley, Minnesota From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International